title: S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.
abstract: OBJECTIVE
  The primary objective of this trial was to evaluate the response rate for trimetrexate in conjunction with 5-FU and leucovorin (LV) (= TFL) in the treatment of advanced gastric cancer in a phase II, cooperative group setting.
  
  
  METHODS
  Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours x 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression.
  
  
  RESULTS
  Characteristics for 37 eligible patients: median age 63 (range: 23-83); male/female: 69% of 31%; performance status 0/1/2 15/20/1. The confirmed response rate was 19%, and median overall survival was 6 months. Two patients died as a result of therapy, 1 because of infection without significant neutropenia, and 1 due to perforation of a responding gastric lesion. Seventy-two percent experienced grades 3 and 4 toxicity, most commonly diarrhea, fatigue, and lymphopenia.
  
  
  CONCLUSIONS
  This regimen achieves response rates comparable to other 5-FU-based regimens, when used in treatment of incurable gastric cancer. Toxicity appears manageable.
authors.affiliation: Division of Medical Oncology, University of British Columbia and British Columbia Cancer Agency, Vancouver, BC. cblanke@bccancer.bc.ca
authors.forename: Charles D
authors.initials: CD
authors.lastname: Blanke
authors.forename: Kari
authors.initials: K
authors.lastname: Chansky
authors.forename: Kathy L
authors.initials: KL
authors.lastname: Christman
authors.forename: Scott A
authors.initials: SA
authors.lastname: Hundahl
authors.forename: Brian F
authors.initials: BF
authors.lastname: Issell
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Van Veldhuizen
authors.forename: G Thomas
authors.initials: GT
authors.lastname: Budd
authors.forename: James L
authors.initials: JL
authors.lastname: Abbruzzese
authors.forename: John S
authors.initials: JS
authors.lastname: Macdonald
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate; D016896:Treatment Outcome; D016597:Trimetrexate / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D002955:Leucovorin; D005472:Fluorouracil; D016597:Trimetrexate